Paclitaxel enhancer compounds

US7368473B2 · kind B2 · utility

Assignee

• Synta Pharmaceuticals Corp. · US

Inventors

• Keizo Koya · Sharon, US
• Lijun Sun · Harvard, US
• Shoujun Chen · Bedford, US
• Noriaki Tatsuta · Lexington, US
• Yaming Wu · Shanghai, CN
• Mitsunori Ono · Lexington, US
• Zhi-Qiang Xia · Acton, US

Key dates

• Filing date: Oct 5, 2005
• Grant date: May 6, 2008
• Expiry date: Apr 15, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2601/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

One embodiment of the present invention is a compound represented by the Structural Formula (I):Y is a covalent bond of a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C═Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R7R8)—.R1 is an aliphatic group, a substituted aliphatic group, a non-aromatic heterocyclic group, or a substituted non-aromatic heterocyclic group, R2-R4 are independently —H, an aliphatic group, a substituted aliphatic group, a non-aromatic heterocyclic group, a substituted non-aromatic heterocyclic group, an aryl group or a substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring.R5-R6 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group.R7 and R8 are each independently —H, an aliphatic or substituted aliphatic group, or R7 is —H and R8 is a substituted…